

David Jw Grant

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11444410/publications.pdf>

Version: 2024-02-01

68
papers

4,600
citations

101543

36
h-index

106344

65
g-index

68
all docs

68
docs citations

68
times ranked

2975
citing authors

#	ARTICLE	IF	CITATIONS
1	Crystalline solids. <i>Advanced Drug Delivery Reviews</i> , 2001, 48, 3-26.	13.7	625
2	Pharmaceutical hydrates. <i>Thermochimica Acta</i> , 1995, 248, 61-79.	2.7	459
3	Physical Stability of Amorphous Pharmaceuticals: Importance of Configurational Thermodynamic Quantities and Molecular Mobility. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 1863-1872.	3.3	292
4	Polymorph screening: Influence of solvents on the rate of solvent-mediated polymorphic transformation. <i>Journal of Pharmaceutical Sciences</i> , 2001, 90, 1878-1890.	3.3	263
5	Polymorph screening: Influence of solvents on the rate of solvent-mediated polymorphic transformation. <i>Journal of Pharmaceutical Sciences</i> , 2001, 90, 1878-1890.	3.3	197
6	Hydrogen bonding in sulfonamides. <i>Journal of Pharmaceutical Sciences</i> , 2001, 90, 2058-2077.	3.3	167
7	Crystallization and Transitions of Sulfamerazine Polymorphs. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 1089-1100.	3.3	108
8	Characterization of Racemic Species of Chiral Drugs Using Thermal Analysis, Thermodynamic Calculation, and Structural Studies. <i>Journal of Pharmaceutical Sciences</i> , 1999, 88, 337-346.	3.3	107
9	Influence of water activity in organic solvent + water mixtures on the nature of the crystallizing drug phase. 2. Ampicillin. <i>International Journal of Pharmaceutics</i> , 1996, 139, 33-43.	5.2	101
10	Effects of initial particle size on the tableting properties of l-lysine monohydrochloride dihydrate powder. <i>International Journal of Pharmaceutics</i> , 2001, 215, 221-228.	5.2	101
11	Estimating the relative stability of polymorphs and hydrates from heats of solution and solubility data. <i>Journal of Pharmaceutical Sciences</i> , 2001, 90, 1277-1287.	3.3	100
12	Identifying the Stable Polymorph Early in the Drug Discovery/Development Process. <i>Pharmaceutical Development and Technology</i> , 2005, 10, 291-297.	2.4	93
13	Physical properties of parabens and their mixtures: Solubility in water, thermal behavior, and crystal structures. <i>Journal of Pharmaceutical Sciences</i> , 1999, 88, 1210-1216.	3.3	85
14	Crystallization Kinetics of Amorphous Nifedipine Studied by Model-Fitting and Model-Free Approaches. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 1779-1792.	3.3	83
15	Relationship Between Physical Properties and Crystal Structures of Chiral Drugs. <i>Journal of Pharmaceutical Sciences</i> , 1997, 86, 1073-1078.	3.3	81
16	Stabilization of a metastable polymorph of sulfamerazine by structurally related additives. <i>Journal of Crystal Growth</i> , 2002, 235, 471-481.	1.5	81
17	Influence of Crystal Shape on the Tableting Performance of L-Lysine Monohydrochloride Dihydrate. <i>Journal of Pharmaceutical Sciences</i> , 2001, 90, 569-579.	3.3	73
18	Quantitation of crystalline and amorphous forms of anhydrous neotame using ¹³ C CPMAS NMR spectroscopy. <i>Journal of Pharmaceutical Sciences</i> , 2005, 94, 2591-2605.	3.3	73

#	ARTICLE	IF	CITATIONS
19	Crystallisation of paracetamol (acetaminophen) in the presence of structurally related substances. <i>Journal of Crystal Growth</i> , 1998, 183, 629-640.	1.5	70
20	Solid-state behavior of cromolyn sodium hydrates. <i>Journal of Pharmaceutical Sciences</i> , 1999, 88, 1191-1200.	3.3	65
21	The effect of structurally related substances on the nucleation kinetics of paracetamol (acetaminophen). <i>Journal of Crystal Growth</i> , 1995, 156, 252-260.	1.5	63
22	Determination of water content in pharmaceutical hydrates by differential scanning calorimetry. <i>International Journal of Pharmaceutics</i> , 1992, 82, 117-127.	5.2	62
23	Solid State Stability Studies of Model Dipeptides: Aspartame and Aspartylphenylalanine. <i>Journal of Pharmaceutical Sciences</i> , 1997, 86, 64-71.	3.3	56
24	Dehydration kinetics of piroxicam monohydrate and relationship to lattice energy and structure. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 3013-3026.	3.3	56
25	A Calorimetric Investigation of Thermodynamic and Molecular Mobility Contributions to the Physical Stability of Two Pharmaceutical Glasses. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 71-83.	3.3	55
26	Molecular Modeling Study Of Chiral Drug Crystals: Lattice Energy Calculations. <i>Journal of Pharmaceutical Sciences</i> , 2001, 90, 1523-1539.	3.3	51
27	Racemic species of sodium ibuprofen: Characterization and polymorphic relationships. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 1356-1366.	3.3	51
28	Model-free treatment of the dehydration kinetics of nedocromil sodium trihydrate. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 1367-1376.	3.3	48
29	Solid-State Characterization of Two Polymorphs of Aspartame Hemihydrate. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 501-507.	3.3	46
30	Influence of crystal structure on the tableting properties of n-alkyl 4-hydroxybenzoate esters (parabens). <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 3324-3333.	3.3	46
31	A disruption index for quantifying the solid state disorder induced by additives or impurities. I. Definition and evaluation from heat of fusion. <i>International Journal of Pharmaceutics</i> , 1985, 25, 57-72.	5.2	45
32	A disruption index for quantifying the solid state disorder induced by additives or impurities. II. Evaluation from heat of solution. <i>International Journal of Pharmaceutics</i> , 1986, 28, 103-112.	5.2	44
33	Influence of compaction on the intrinsic dissolution rate of modified acetaminophen and adipic acid crystals. <i>International Journal of Pharmaceutics</i> , 1989, 57, 117-124.	5.2	43
34	Physical characterization of nedocromil sodium hydrates. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 1052-1061.	3.3	41
35	The use of thermal analysis in the assessment of crystal disruption. <i>Thermochimica Acta</i> , 1995, 248, 131-145.	2.7	38
36	Physicochemical Characterization of Nedocromil Bivalent Metal Salt Hydrates. 1. Nedocromil Magnesium. <i>Journal of Pharmaceutical Sciences</i> , 1996, 85, 1026-1034.	3.3	37

#	ARTICLE	IF	CITATIONS
37	Hydration and Dehydration Behavior of Aspartame Hemihydrate. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 508-513.	3.3	37
38	Relationship between the Structure and Properties of Pharmaceutical Crystals. <i>KONA Powder and Particle Journal</i> , 2005, 23, 36-48.	1.7	37
39	Stable-Form Screening: Overcoming Trace Impurities That Inhibit Solution-Mediated Phase Transformation to the Stable Polymorph of Sulfamerazine. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 2130-2144.	3.3	37
40	Entropy of processing: a new quantity for comparing the solid state disorder of pharmaceutical materials. <i>International Journal of Pharmaceutics</i> , 1986, 30, 161-180.	5.2	36
41	True density and thermal expansivity of pharmaceutical solids: comparison of methods and assessment of crystallinity. <i>International Journal of Pharmaceutics</i> , 1986, 28, 75-84.	5.2	36
42	Dehydration kinetics of neotame monohydrate. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 1423-1431.	3.3	35
43	Investigation of Polymorphism in Aspartame and Neotame Using Solid-State NMR Spectroscopy. <i>Tetrahedron</i> , 2000, 56, 6603-6616.	1.9	34
44	Physicochemical Characterization of Nedocromil Bivalent Metal Salt Hydrates. 2. Nedocromil Zinc. <i>Journal of Pharmaceutical Sciences</i> , 1997, 86, 418-429.	3.3	30
45	Dehydration behavior of eprosartan mesylate dihydrate. <i>Journal of Pharmaceutical Sciences</i> , 1999, 88, 1021-1029.	3.3	30
46	Dehydration behavior of nedocromil magnesium pentahydrate. <i>International Journal of Pharmaceutics</i> , 2001, 215, 251-262.	5.2	25
47	Modification of acetaminophen crystals. III. Influence of initial supersaturation during solution-phase growth on crystal properties in the presence and absence of p-acetoxyacetanilide. <i>International Journal of Pharmaceutics</i> , 1988, 42, 123-133.	5.2	23
48	Enthalpy-entropy compensation in pharmaceutical solids. <i>International Journal of Pharmaceutics</i> , 1987, 40, 1-14.	5.2	21
49	Effect of the opposite enantiomer on the physicochemical properties of (-)-ephedrinium 2-naphthalenesulfonate crystals. <i>International Journal of Pharmaceutics</i> , 1993, 94, 171-179.	5.2	20
50	Determination of the solubilities of crystalline solids in solvent media that induce phase changes: Solubilities of 1,2-dialkyl-3-hydroxy-4-pyridones and their formic acid solvates in formic acid and water. <i>International Journal of Pharmaceutics</i> , 1995, 114, 185-196.	5.2	20
51	A theoretical treatment of changes in energy and entropy of solids caused by additives or impurities in solid solution. <i>International Journal of Pharmaceutics</i> , 1987, 39, 243-253.	5.2	18
52	Solid State Properties of an Oral Iron Chelator, 1,2-Dimethyl-3-hydroxy-4-pyridone, and Its Acetic Acid Solvate. I: Physicochemical Characterization, Intrinsic Dissolution Rate, and Solution Thermodynamics. <i>Journal of Pharmaceutical Sciences</i> , 1991, 80, 677-685.	3.3	18
53	Effects of crystallization in the presence of the opposite enantiomer on the crystal properties of (ss)-(+)-pseudoephedrinium salicylate. <i>International Journal of Pharmaceutics</i> , 1996, 127, 53-63.	5.2	18
54	Effects of excess enantiomer on the crystal properties of a racemic compound: ephedrinium 2-naphthalenesulfonate. <i>International Journal of Pharmaceutics</i> , 1996, 137, 21-31.	5.2	18

#	ARTICLE	IF	CITATIONS
55	Solid-state properties of warfarin sodium 2- α -propranol solvate. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2669-2680.	3.3	17
56	Physical factors influencing the aqueous dissolution rate of acetaminophen crystals doped with p-acetoxyacetanilide: evaluation by multiple linear regression. <i>International Journal of Pharmaceutics</i> , 1989, 51, 129-135.	5.2	16
57	Modification of acetaminophen crystals. II. Influence of stirring rate during solution-phase growth on crystal properties in the presence and absence of p-acetoxyacetanilide. <i>International Journal of Pharmaceutics</i> , 1988, 41, 29-39.	5.2	13
58	Influence of crystallization conditions on the physical properties of acetaminophen crystals: evaluation by multiple linear regression. <i>International Journal of Pharmaceutics</i> , 1989, 51, 115-127.	5.2	11
59	Crystal structure and physical characterization of neotame methanol solvate. <i>Journal of Chemical Crystallography</i> , 1999, 29, 967-975.	1.1	9
60	Crystal structure and thermal behavior of nedocromil nickel octahydrate. <i>International Journal of Pharmaceutics</i> , 2002, 232, 23-33.	5.2	9
61	Locating the impurity in doped crystals using isotopic double labelling and a column α -flow-through dissolution cell: adipic acid doped with oleic acid. <i>International Journal of Pharmaceutics</i> , 1987, 36, 17-28.	5.2	8
62	Principles of Solubility. , 2007, , 1-27.		8
63	Relationships between Solution Thermodynamics and Hydrogen-Bond Patterns of Crystalline Dialkylhydroxypyridone Iron Chelators and Their Formic Acid Solvates. <i>Journal of Pharmaceutical Sciences</i> , 1995, 84, 568-574.	3.3	4
64	Conformational flexibility and hydrogen-bonding patterns of the neotame molecule in its various solid forms. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 2047-2056.	3.3	2
65	Physical properties and enantiomeric composition. , 2006, , 47-77.		2
66	Crystal structures of the benzene and ethanol solvates of neotame. <i>Journal of Chemical Crystallography</i> , 2003, 33, 787-793.	1.1	1
67	N4-Acetylsulfamerazine. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2006, 62, o4245-o4246.	0.2	1
68	Title is missing!. <i>Pharmaceutical Research</i> , 2000, 17, 1439-1442.	3.5	0